The National Institute for Health and Care Excellence published a draft guideline on 1 July 2026 that recommends annual reviews for people diagnosed with polyendocrine metabolic ovarian syndrome.
The condition, previously known as polycystic ovary syndrome until its name changed in May 2026, affects approximately one in eight women. It is frequently under-diagnosed and managed inconsistently across the health service.
Under the proposals, those with the diagnosis would receive a structured annual review. This would track symptoms such as menstrual irregularities and excess hair growth, review medicines in use, and assess risks for serious long-term conditions including type 2 diabetes and cardiovascular disease.
The draft also urges clinicians to investigate women who present with irregular or absent menstrual cycles alongside signs of excessive male hormones. Diagnosis should not be ruled out after the menopause.
Evidence-based approach to diagnosis and care
These steps reflect a deliberate effort to ground clinical practice in observable physiological realities rather than assumptions that symptoms are simply part of normal female experience. Such rigour matters. The condition carries increased risks of type 2 diabetes mellitus, cardiovascular disease, obstructive sleep apnoea, fatty liver disease, mental health problems and complications in pregnancy.
Sharon Manship, a lay member on the guideline committee, described her own three-decade experience with the condition.